The Uromigos Episode 59: Ipatercertib in Biomarker Positive Castrate Resistant Prostate Cancer
Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered castrate resistant prostate cancer. A positive R3 trial in the ESMO plenary session.
670 Madison Ave.
Manalapan, NJ 07726
Contributors and Partners
Cancer Nursing Today
Urban Health Today
Blood Cancers Today
© 2022 Mashup Media, LLC. All rights reserved.